Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation

Insulin-like growth factor (IGF) signaling is fundamental for growth and survival. A large body of evidence (laboratory, epidemiological, and clinical) implicates the exploitation of this pathway in cancer. Up to 50% of breast tumors express the activated form of the type 1 insulin-like growth factor receptor (IGF1R). Breast cancers are categorized into subtypes based upon hormone and ERRB2 receptor expression and/or gene expression profiling. Even though IGF1R influences tumorigenic phenotypes and drug resistance across all breast cancer subtypes, it has specific expression and function in each. In some subtypes, IGF1R levels correlate with a favorable prognosis, while in others it is associated with recurrence and poor prognosis, suggesting different actions based upon cellular and molecular contexts. In this review, we examine IGF1R expression and function as it relates to breast cancer subtype and therapy-acquired resistance. Additionally, we discuss the role of IGF1R in stem cell maintenance and lineage differentiation and how these cell fate influences may alter the differentiation potential and cellular composition of breast tumors.

[1]  T. Miller.  Endocrine resistance: what do we know? , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[2]  S. Liang,et al.  Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway , 2010, Oncogene.

[3]  D. Reinke,et al.  R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[5]  R. Girgert,et al.  Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy , 2012, Breast Cancer Research and Treatment.

[6]  Adrian V. Lee,et al.  Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Werner,et al.  The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action , 2006, Trends in Endocrinology & Metabolism.

[8]  M. De León,et al.  Insulin-like growth factors I and II receptors in the breast cancer survival disparity among African-American women. , 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[9]  A. Belfiore,et al.  Insulin-like growth factor-I regulates GPER expression and function in cancer cells , 2013, Oncogene.

[10]  Matthias Egger,et al.  Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.

[11]  N. Rosenthal,et al.  IGF-1, inflammation and stem cells: interactions during muscle regeneration. , 2005, Trends in immunology.

[12]  N. Dahmane,et al.  Differential Modulation of Sonic-Hedgehog-Induced Cerebellar Granule Cell Precursor Proliferation by the IGF Signaling Network , 2010, Developmental Neuroscience.

[13]  L. Hennighausen,et al.  Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. , 2006, Endocrinology.

[14]  F. Bertrand,et al.  Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activation , 2001, Oncogene.

[15]  Douglas Hanahan,et al.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.

[16]  H. Werner,et al.  HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. , 2010, European journal of cancer.

[17]  D. Leroith,et al.  Decreased IGF type 1 receptor signaling in mammary epithelium during pregnancy leads to reduced proliferation, alveolar differentiation, and expression of insulin receptor substrate (IRS)-1 and IRS-2. , 2011, Endocrinology.

[18]  L. O’Driscoll,et al.  miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer , 2014, Molecular Cancer.

[19]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Scott,et al.  Insulin-like growth factor-II gene expression in Wilms' tumour and embryonic tissues , 1985, Nature.

[21]  Adrian V. Lee,et al.  High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy , 2010, Clinical Cancer Research.

[22]  J. Brunet,et al.  Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). , 2010, International journal of oncology.

[23]  S. Radhakrishnan,et al.  Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways , 2010, BMC Cancer.

[24]  H. Werner,et al.  Functional and Physical Interactions between BRCA1 and p53 in Transcriptional Regulation of the IGF-IR Gene , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[25]  T. Habuchi,et al.  CA repeat polymorphism in the insulin-like growth factor-I gene is associated with increased risk of prostate cancer and benign prostatic hyperplasia. , 2005, International journal of oncology.

[26]  T. Lash,et al.  Triple-negative breast cancers are increased in black women regardless of age or body mass index , 2009, Breast Cancer Research.

[27]  K. Noller,et al.  Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis , 2007, Breast Cancer Research.

[28]  R. Wieczorek,et al.  Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. , 1995, Endocrinology.

[29]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[30]  D. Yee,et al.  Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. , 2012, Cancer research.

[31]  Zhenhua Li,et al.  GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer , 2013, Breast Cancer Research.

[32]  K. Matsuo,et al.  Insulin‐like growth factor (IGF)‐I and IGF‐binding protein 3 and the risk of premenopausal breast cancer: A meta‐analysis of literature , 2004, International journal of cancer.

[33]  B. Leyland-Jones,et al.  Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. , 2006, Cancer research.

[34]  J. Treadway,et al.  Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro. , 1989, The Journal of biological chemistry.

[35]  F. Huang,et al.  Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807. , 2010, Endocrinology.

[36]  T. Nielsen,et al.  Expression of the Insulin-Like Growth Factor I Receptor and Urokinase Plasminogen Activator in Breast Cancer Is Associated with Poor Survival , 2004, Cancer Research.

[37]  Ana Lluch,et al.  Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. , 2012, Cancer treatment reviews.

[38]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[39]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[40]  D. Leroith,et al.  Minireview: IGF, Insulin, and Cancer. , 2011, Endocrinology.

[41]  S. Tsao,et al.  Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor , 2013, Molecular Cancer Therapeutics.

[42]  M. Stampfer,et al.  Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. , 1998, Science.

[43]  A. Brunetti,et al.  A Nucleoprotein Complex Containing Sp1, C/EBPβ, and HMGI-Y Controls Human Insulin Receptor Gene Transcription , 2003, Molecular and Cellular Biology.

[44]  You-hong Cui,et al.  β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. , 2013, Cancer research.

[45]  C. Arteaga,et al.  Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation , 2013, Breast Cancer Research.

[46]  P. Sorensen,et al.  Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy , 2012, Expert opinion on therapeutic targets.

[47]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[48]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[49]  P. Boyle,et al.  Triple-negative breast cancer: epidemiological considerations and recommendations. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  D. Leroith,et al.  Insulin-like Growth Factor 1 (IGF-1)-induced Twist Expression Is Involved in the Anti-apoptotic Effects of the IGF-1 Receptor* , 2001, The Journal of Biological Chemistry.

[51]  A. Belfiore,et al.  GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. , 2014, Endocrine-related cancer.

[52]  A. Ashworth,et al.  BRCA1 dysfunction in sporadic basal-like breast cancer , 2007, Oncogene.

[53]  S. Levison,et al.  Insulin-like Growth Factor-II (IGF-II) and IGF-II Analogs with Enhanced Insulin Receptor-a Binding Affinity Promote Neural Stem Cell Expansion* , 2014, The Journal of Biological Chemistry.

[54]  F. Peruzzi,et al.  Anti-apoptotic Signaling of the Insulin-like Growth Factor-I Receptor through Mitochondrial Translocation of c-Raf and Nedd4* , 2001, The Journal of Biological Chemistry.

[55]  Samuel Leung,et al.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2008, Clinical Cancer Research.

[56]  Sujata Sharma,et al.  Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop Phosphorylation , 2009, The Journal of Biological Chemistry.

[57]  H. Masoudi,et al.  Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. , 2008, Cancer research.

[58]  Adrian V. Lee,et al.  Targeting IGF-1R: at a crossroad. , 2011, Oncology.

[59]  R. Weksberg,et al.  Relaxation of imprinting of human insulin-like growth factor II gene, IGF2, in sporadic breast carcinomas. , 1997, Biochemical and biophysical research communications.

[60]  M. P. Walker,et al.  Mammary gland branching morphogenesis is diminished in mice with a deficiency of insulin-like growth factor-I (IGF-I), but not in mice with a liver-specific deletion of IGF-I. , 2004, Endocrinology.

[61]  S. Leung,et al.  Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes , 2012, Breast Cancer Research and Treatment.

[62]  M. Fernö,et al.  Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer , 2014, BMC Cancer.

[63]  M. Pollak,et al.  The Type 1 Insulin-Like Growth Factor Receptor Pathway , 2008, Clinical Cancer Research.

[64]  A. Ashworth,et al.  BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. , 2010, Cell stem cell.

[65]  W. Ruan,et al.  Insulin-Like Growth Factor I Is Essential for Terminal End Bud Formation and Ductal Morphogenesis during Mammary Development1. , 1999, Endocrinology.

[66]  Charles M Perou,et al.  Systems biology and genomics of breast cancer. , 2011, Cold Spring Harbor perspectives in biology.

[67]  X. Shu,et al.  Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study , 2007, Breast Cancer Research and Treatment.

[68]  H. Hsu,et al.  Insulin signals control the competence of the Drosophila female germline stem cell niche to respond to Notch ligands. , 2011, Developmental biology.

[69]  C. Kahn,et al.  Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland. , 2003, Endocrinology.

[70]  D. Yee,et al.  Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. , 2007, Cancer research.

[71]  P. Ye,et al.  β‐catenin mediates insulin‐like growth factor‐I actions to promote cyclin D1 mRNA expression, cell proliferation and survival in oligodendroglial cultures , 2010, Glia.

[72]  H. Werner,et al.  Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells , 2010, Cancers.

[73]  Sean C. Bendall,et al.  IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro , 2007, Nature.

[74]  J. Attems,et al.  Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. , 2007, Endocrine-related cancer.

[75]  A. Roessner,et al.  G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer , 2011, Breast Cancer Research and Treatment.

[76]  S. Hilsenbeck,et al.  Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. , 1999, Molecular endocrinology.

[77]  R. Shi,et al.  IGF‐I and breast cancer: A meta‐analysis , 2004, International journal of cancer.

[78]  D. Hadsell,et al.  Targeted disruption of the IGF-I receptor gene decreases cellular proliferation in mammary terminal end buds. , 2001, Endocrinology.

[79]  Xiaochu Yan,et al.  Nanog regulates self‐renewal of cancer stem cells through the insulin‐like growth factor pathway in human hepatocellular carcinoma , 2012, Hepatology.

[80]  M. White,et al.  IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. , 1993, Endocrinology.

[81]  M. Ellis,et al.  Insulin-like growth factors in human breast cancer , 2004, Breast Cancer Research and Treatment.

[82]  F. Bertrand,et al.  Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. , 2001, Oncogene.

[83]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[84]  Stefan Glück,et al.  Molecular Profiling for Breast Cancer: A Comprehensive Review , 2013, Biomarkers in cancer.

[85]  David J Hunter,et al.  Circulating concentrations of insulin-like growth factor I and risk of breast cancer , 1998, The Lancet.

[86]  R. Naeije,et al.  Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy , 2009, BMC cardiovascular disorders.

[87]  J. Lee,et al.  Positive Expression of Insulin-Like Growth Factor-1 Receptor Is Associated with a Positive Hormone Receptor Status and a Favorable Prognosis in Breast Cancer , 2014, Journal of breast cancer.

[88]  T. Habuchi.  Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. , 2006, Future oncology.

[89]  C. Singer,et al.  Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[90]  N. Joste,et al.  GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer , 2010, Breast Cancer Research and Treatment.

[91]  T. Smeal,et al.  Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells , 2012, PloS one.

[92]  K. Hemminki,et al.  Polymorphisms in the IGF-1 and IGFBP3 promoter and the risk of breast cancer , 2005, Breast Cancer Research and Treatment.

[93]  Adrian V. Lee,et al.  Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. , 2012, Critical reviews in oncogenesis.

[94]  Y. Seong,et al.  BRCA1 negatively regulates IGF-1 expression through an estrogen-responsive element-like site , 2012, Cell Death and Disease.

[95]  T. Ouchi,et al.  BRCA1–Sp1 interactions in transcriptional regulation of the IGF‐IR gene , 2003, FEBS letters.

[96]  Lei Wang,et al.  Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R , 2014, BMC Cancer.

[97]  J. McManaman,et al.  Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. , 2010, Cancer research.

[98]  Jyh‐cherng Yu,et al.  The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors , 2013, Breast Cancer Research.

[99]  D. Hadsell,et al.  Genetic manipulation of the IGF-I axis to regulate mammary gland development and function. , 2002, Journal of dairy science.

[100]  K. Siddle,et al.  Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  A. Lykkesfeldt,et al.  Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha. , 2003, Endocrine-related cancer.

[102]  D. Leroith,et al.  IGF1R inhibition in mammary epithelia promotes canonical Wnt signaling and Wnt1-driven tumors. , 2014, Cancer research.

[103]  Keunchil Park,et al.  Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  M. Dowsett,et al.  Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  S. Koujak,et al.  Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer , 2010, Molecular Cancer Therapeutics.

[106]  G. Hortobagyi,et al.  The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins , 2004, British Journal of Cancer.

[107]  W. Ruan,et al.  Non-lactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland. , 1990, Endocrinology.

[108]  A. Tolcher,et al.  Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  R. Schiff,et al.  Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. , 2008, Cancer research.

[110]  E. Winer,et al.  Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.

[111]  Young Sam Kim,et al.  Promoter −202 A/C polymorphism of insulin‐like growth factor binding protein‐3 gene and non‐small cell lung cancer risk , 2006 .

[112]  W. Bodmer,et al.  Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[113]  S. Andò,et al.  Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells , 1999, International journal of cancer.

[114]  G. Rao,et al.  Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice , 2004, Oncogene.

[115]  High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling , 2011, The Journal of experimental medicine.

[116]  Adrian V. Lee,et al.  Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail , 2007, Molecular and Cellular Biology.

[117]  Zoë Davison,et al.  Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. , 2011, Neoplasia.

[118]  P. Walden,et al.  Evidence that the mammary fat pad mediates the action of growth hormone in mammary gland development. , 1998, Endocrinology.

[119]  M. Tatar,et al.  The Endocrine Regulation of Aging by Insulin-like Signals , 2003, Science.

[120]  V. Duronio,et al.  Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. , 1989, The Journal of biological chemistry.

[121]  A. Roessner,et al.  Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells , 2010, Breast Cancer Research and Treatment.

[122]  J. Szemraj,et al.  Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer. , 2012, Neoplasma.

[123]  Adrian V. Lee,et al.  Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2 , 2006, Molecular and Cellular Biology.

[124]  W. Ruan,et al.  IGF-I, GH, and Sex Steroid Effects in Normal Mammary Gland Development , 2008, Journal of Mammary Gland Biology and Neoplasia.

[125]  L. Kuo,et al.  Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. , 2003, Acta crystallographica. Section D, Biological crystallography.

[126]  J. Robertson,et al.  Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. , 2013, The Lancet. Oncology.

[127]  A. Belfiore,et al.  Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved* , 2002, The Journal of Biological Chemistry.

[128]  O. Kamel,et al.  Biology of the estrogen receptor, GPR30, in triple negative breast cancer. , 2013, American journal of surgery.

[129]  S. Gammeltoft,et al.  Chromaffin cells express two types of insulin-like growth factor receptors , 1990, Brain Research.

[130]  Adrian V. Lee,et al.  The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells. , 2011, Molecular endocrinology.

[131]  J. Ashwell,et al.  Activating p38 MAPK: New Tricks for an Old Kinase , 2005, Cell cycle.

[132]  K. Takahashi,et al.  Association of insulin‐like growth‐factor‐I‐induced DNA synthesis with phosphorylation and nuclear exclusion of p53 in human breast cancer MCF‐7 cells , 1993, International journal of cancer.

[133]  A. Rowzee,et al.  Growth Factor Regulation of Cell Cycle Progression in Mammary Epithelial Cells , 2004, Journal of Mammary Gland Biology and Neoplasia.

[134]  Y. Chang,et al.  Promoter −202 A/C polymorphism of insulin‐like growth factor binding protein‐3 gene and non‐small cell lung cancer risk , 2005, International journal of cancer.

[135]  R. Yarden,et al.  Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. , 2007, Cancer letters.

[136]  K. Hess,et al.  Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. , 2010, Gastroenterology.

[137]  R. Shi,et al.  Polymorphic CA repeats in the IGF-I gene and breast cancer , 2001, Breast Cancer Research and Treatment.

[138]  Marja Moerkens,et al.  Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes , 2011, Breast Cancer Research.

[139]  A. Osunkoya,et al.  Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. , 2008, Cancer research.

[140]  Lajos Pusztai,et al.  Gene expression profiling of breast cancer , 2009, Breast Cancer Research.

[141]  M. Fernö,et al.  Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer , 2014, Breast Cancer Research and Treatment.

[142]  K. Siddle,et al.  Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. , 1989, The Biochemical journal.

[143]  D. Leroith,et al.  Insulin-like Growth Factors and Cancer , 1995, Annals of Internal Medicine.

[144]  O. Larsson,et al.  Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[145]  R. Nicholson,et al.  Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. , 2005, Endocrinology.

[146]  H. Senn,et al.  Insulin-like growth factors and cancer. , 2002, The Lancet. Oncology.

[147]  Adrian V. Lee,et al.  Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1. , 2006, The Journal of endocrinology.

[148]  A. Thor,et al.  Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions , 2011, Cell cycle.

[149]  J. McCubrey,et al.  Synergy between PI3K/Akt and Raf/MEK/ERK Pathways in IGF-1R Mediated Cell Cycle Progression and Prevention of Apoptosis in Hematopoietic Cells , 2004, Cell cycle.

[150]  R. Nahta,et al.  Insulin-Like Growth Factor-1 Receptor Signaling Increases the Invasive Potential of Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer Cells via Src-Focal Adhesion Kinase and Forkhead Box Protein M1 , 2015, Molecular Pharmacology.

[151]  J. Beattie,et al.  Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. , 2013, Biochimica et biophysica acta.

[152]  Zhijun Tang,et al.  Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake , 2008, Molecular Cancer Therapeutics.

[153]  J. Ketelslegers,et al.  Nutritional regulation of the insulin-like growth factors. , 1994, Endocrine reviews.

[154]  D. Dabbs,et al.  Insulin-like Growth Factor Receptor-1 (IGF-1R) Expression in Normal Breast, Proliferative Breast Lesions, and Breast Carcinoma , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[155]  A. Belfiore,et al.  Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. , 2011, The Journal of clinical endocrinology and metabolism.

[156]  G. Bernardi,et al.  Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[157]  B. Wasylyk,et al.  Ets ternary complex transcription factors. , 2004, Gene.

[158]  R. Nahta.  Deciphering the Role of Insulin-Like Growth Factor-I Receptor in Trastuzumab Resistance , 2012, Chemotherapy research and practice.

[159]  M. Duffy,et al.  Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours , 2012, Breast Cancer Research and Treatment.

[160]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[161]  B. Kreike,et al.  Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma , 2011, Breast Cancer Research and Treatment.

[162]  D. Yee,et al.  Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer , 2012, Journal of Mammary Gland Biology and Neoplasia.

[163]  D. Altshuler,et al.  Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. , 2006, Journal of the National Cancer Institute.

[164]  S. Leung,et al.  Insulin-like growth factor receptor ( IGF-1 R ) in breast cancer subtypes , 2012 .

[165]  E. Monti,et al.  Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells , 2014, British Journal of Cancer.

[166]  A. Belfiore,et al.  The Emerging Role of Insulin and Insulin-Like Growth Factor Signaling in Cancer Stem Cells , 2014, Front. Endocrinol..